ROSEVILLE, Minn., Feb. 7, 2022 /PRNewswire/ -- Calyxt,
Inc. (Nasdaq: CLXT), a plant-based synthetic biotechnology
company, today announced that Gerry
Nuovo has joined Calyxt as Senior Vice President of Business
Development. He brings more than 30 years of experience in the
specialty chemicals and biotechnology industries and diverse
experience building multimillion-dollar income streams in the
personal care and home care markets. Mr. Nuovo will be responsible
for business development functions, including potential
partnerships, deal structures, valuation models, and subsequent
transaction execution and alliance management.
"We're thrilled to welcome Gerry at this exciting time for our
team," said Michael A. Carr,
President and Chief Executive Officer of Calyxt. "His experience is
well aligned with our strategy to deliver plant-based synthetic
biology solutions to important new customers in identified key end
markets, and his track record in cosmetics, nutraceuticals and
beauty is particularly timely as we continue to focus our business
development efforts on these and other key markets, helping
customers produce products that meet their corporate sustainability
goals."
"Calyxt is a synthetic biology company that delivers unique and
innovative plant-based solutions not available through other
production methods, and the integration of its proprietary
PlantSpring™ technology platform with its BioFactory™ production
system, enables Calyxt to rapidly prototype and produce complex
plant-derived compounds," said Mr. Nuovo. "It's a compelling and
differentiated offering for customers, and I look forward to
working alongside this dynamic executive team."
Mr. Nuovo most recently served as Vice President of
Commercialization & Global Business Development at C16
Biosciences, where he led global commercialization of its novel
technology platform focused on an alternative to conflict
agricultural palm oil and downstream derivatives. Prior, he served
as Sales Director, Americas, Personal Care at Cargill, Inc. and as
Vice President, Global Market Development, Consumer Products at
Rivertop Renewables. Previously, Mr. Nuovo held senior business
development and sales roles at Segetis, Codexis, Inc., and
Firmenich, Inc.
Mr. Nuovo holds a B.S. in Biology and Chemistry from
William Paterson University of New
Jersey.
About Calyxt:
Calyxt (Nasdaq: CLXT) is a plant-based synthetic biotechnology
company. The Company leverages its proprietary PlantSpring™
technology platform to engineer innovative materials and products
for its customers to help them meet their sustainability goals.
Calyxt's diversified offerings are primarily delivered through its
proprietary BioFactory™ production system. For more information,
visit www.calyxt.com.
PlantSpring, BioFactory, Plant Cell Matrix™, and the Calyxt logo
are trademarks of Calyxt, Inc. Any other trademarks belong to their
respective owners.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. In some cases, you can
identify these statements by forward-looking words such as
"anticipates," "believes," "continue," "estimates," "expects,"
"intends," "may," "might," "plans," "predicts," "projects,"
"should," "targets," "will," or the negative of these terms and
other similar terminology. Forward-looking statements in this press
release include statements about Calyxt's product pipeline and
development; Calyxt's ability to utilize the BioFactory to engineer
precursor molecules and to convert these to broader chemistries
demanded by potential customers; Calyxt's ability to achieve target
molecule production and performance at greater scale; and the
commercial demand for Calyxt's synthetic biology solutions. These
and other forward-looking statements are predictions and
projections about future events and trends based on Calyxt's
current expectations, objectives, and intentions and are premised
on current assumptions. Calyxt's actual results, level of activity,
performance, or achievements could be materially different than
those expressed, implied, or anticipated by forward-looking
statements due to a variety of factors, including, but not limited
to: the impact of increased competition, including competition from
a broader array of synthetic biology companies; disruptions at
Calyxt's key facilities, including disruptions impacting its
BioFactory production system; changes in customer preferences and
market acceptance of Calyxt's products; competition for customers,
partners, and licensees and the successful execution of development
and licensing agreements; the impact of adverse events during
development, including unsuccessful pilot production of compounds
or generation of inconsistent data; disruptions to supply chains,
including raw material inputs for Calyxt's BioFactory; the impact
of changes or increases in oversight and regulation; disputes or
challenges regarding intellectual property; proliferation and
continuous evolution of new technologies; and other important
factors discussed under the caption entitled "Risk Factors" in
Calyxt's Annual Report on Form 10-K and subsequent filings on Form
10-Q or Form 8-K with the U.S. Securities and Exchange Commission.
Any forward-looking statements made by Calyxt's management are
based only on information currently available to it when, and speak
only as of the date, such statement is made. Calyxt does not assume
any obligation to publicly provide revisions or updates to any
forward-looking statements, whether as a result of new information,
future developments or otherwise, should circumstances change,
except as otherwise required by law.
Contacts:
Calyxt Media Contact:
David
Rosen/ John Garabo/
Michael Barron
Argot Partners
(212) 600-1902
media@calyxt.com
Calyxt Investor Relations Contact:
Kimberly Minarovich/ Cameron Willis
Argot Partners
(212) 600-1902
investors@calyxt.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/calyxt-announces-gerry-nuovo-as-senior-vice-president-of-business-development-301475550.html
SOURCE Calyxt, Inc.